Browse Category

CSE:DIAL News 8 August 2025

Complete Guide to Internet Access in Sri Lanka: Fiber, 4G, and Satellite Expansion

Complete Guide to Internet Access in Sri Lanka: Fiber, 4G, and Satellite Expansion

As of early 2025, Sri Lanka has 29.3 million mobile subscriptions, exceeding its population. SLT’s national fiber backbone spans about 45,000 km. By mid-2022, SLT had infrastructure for 1 million fiber connections, with about 500,000 households connected, and aimed to reach 2 million by end-2023. 4G LTE coverage is essentially 100% of the population as of 2024, with 2G nearly 100%. Dialog Axiata and Mobitel have begun pre-commercial 5G trials, with live test zones in Colombo delivering speeds over 500 Mbps. TRCSL licensed SpaceX Starlink Lanka in August 2024 to provide nationwide satellite broadband under a five-year license. In March
8 August 2025

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop